Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Column

Pharma Insights
Formulary Exclusion Lists Create Challenges for Pharma and Payers Alike
10/12/2016
Andrew Cournoyer, RPh, MBA
Larry Blandford, PharmD—Column Editor
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The...
10/12/2016
Journal of Clinical Pathways
Clinical Pathways GPS
The Future of Clinical Pathways: The Potential Impact of the Presidential Election
10/12/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
Although the topic of health care will continue to be a political one, the continued growth of public health care spending suggests that the government will need to continue its shift toward improving the value of...
Although the topic of health care will continue to be a political one, the continued growth of public health care spending suggests that the government will need to continue its shift toward improving the value of...
...
10/12/2016
Journal of Clinical Pathways
Editor's Page
Accounting for Patient Differences in the Pathway
10/12/2016
Winston Wong, PharmD, Editor-in-Chief
At the first Clinical Pathways Congress (September 16-18; Boston, MA), the official meeting of Journal of Clinical Pathways, one of the themes that came up continuously throughout the meeting was the importance of...
At the first Clinical Pathways Congress (September 16-18; Boston, MA), the official meeting of Journal of Clinical Pathways, one of the themes that came up continuously throughout the meeting was the importance of...
At the...
10/12/2016
Journal of Clinical Pathways

Advertisement

Counterpoint
The Pivot Toward Patient-Centeredness in Medicine and Oncology
09/06/2016
Bruce Feinberg, DO
Julia Braverman, PhD
Jennifer Fillman, MBA
Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...
Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...
...
09/06/2016
Journal of Clinical Pathways
Counterpoint
Incorporating Routine Patient-Reported Outcomes Assessment Into Cancer Care: Building Momentum
09/06/2016
Edward Stepanski, PhD
While the collection and reporting of patient-reported outcome data in oncology trials and care settings has yet to reach its full potential, it has made some progress in recent years. Patient-reported outcomes...
While the collection and reporting of patient-reported outcome data in oncology trials and care settings has yet to reach its full potential, it has made some progress in recent years. Patient-reported outcomes...
While...
09/06/2016
Journal of Clinical Pathways
Viewpoint
The Limitations of Patient-Reported Outcome Measurement in Oncology
09/06/2016
Stephen P McKenna, PhD, AFBPsS, CPsychol
Generic patient-reported outcome measures (PROMs) for cancer have outlived their utility. More relevant and accurate PROMs are required in order to demonstrate the true value of oncology interventions to...
Generic patient-reported outcome measures (PROMs) for cancer have outlived their utility. More relevant and accurate PROMs are required in order to demonstrate the true value of oncology interventions to...
...
09/06/2016
Journal of Clinical Pathways

Advertisement

Clinical Pathways GPS
Population Health Delivery Through Health Systems and Pharma
09/06/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
As health systems become more prevalent, they are having increasing levels of control over treatment decisions, in coordination with physicians and managed care organizations. As a result of this increased level of...
As health systems become more prevalent, they are having increasing levels of control over treatment decisions, in coordination with physicians and managed care organizations. As a result of this increased level of...
As...
09/06/2016
Journal of Clinical Pathways
Pharma Insights
Clarity Regarding Prostate Cancer Screening, Why Payers Need It Too
09/06/2016
Jeremy Schafer, PharmD, MBA
Controversy over the lack of a survival benefit associated with early diagnosis of prostate cancer through prostate-specific antigen (PSA) screening has led to uncertainty in the determination of PSA coverage and its...
Controversy over the lack of a survival benefit associated with early diagnosis of prostate cancer through prostate-specific antigen (PSA) screening has led to uncertainty in the determination of PSA coverage and its...
...
09/06/2016
Journal of Clinical Pathways
Editor's Page
A Greater Focus on the Patient
09/06/2016
Winston Wong, PharmD, Editor-in-Chief
One of the core goals of clinical pathways development has always been to make health care more patient-centered. However, a common complaint regarding clinical pathway development is that patients are often left out...
One of the core goals of clinical pathways development has always been to make health care more patient-centered. However, a common complaint regarding clinical pathway development is that patients are often left out...
One of...
09/06/2016
Journal of Clinical Pathways

Advertisement

Pharma Insights
The Rising Use of Oncology Value Tools By Payers
08/02/2016
Jeremy Schafer, PharmD, MBA
Kellie Rademacher, PharmD
Janet Serluco, MS
Attributing value in the rapidly expanding oncology space is a new challenge to payers looking to introduce a range of novel therapies where older drugs have long dominated. Rising costs across all levels of cancer...
Attributing value in the rapidly expanding oncology space is a new challenge to payers looking to introduce a range of novel therapies where older drugs have long dominated. Rising costs across all levels of cancer...
...
08/02/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use